195 related articles for article (PubMed ID: 33938166)
21. The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
Ma VT; Daignault-Newton S; Waninger JJ; Journey S; Chopra Z; Tezel A; Redman BG; Fecher LA; Green MD; Alva AS; Lao CD
Pigment Cell Melanoma Res; 2021 May; 34(3):629-640. PubMed ID: 33128316
[TBL] [Abstract][Full Text] [Related]
22. Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience.
Indini A; Di Guardo L; Cimminiello C; Lorusso D; Raspagliesi F; Del Vecchio M
J Gynecol Oncol; 2019 Nov; 30(6):e94. PubMed ID: 31576688
[TBL] [Abstract][Full Text] [Related]
23. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
Huffman BM; Kottschade LA; Kamath PS; Markovic SN
Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
[TBL] [Abstract][Full Text] [Related]
24. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
25. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of nivolumab in advanced melanoma: a drug review.
Specenier P
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):13-28. PubMed ID: 33225752
[No Abstract] [Full Text] [Related]
27. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
Finger PT; Pavlick AC
J Immunother Cancer; 2019 Mar; 7(1):83. PubMed ID: 30909967
[TBL] [Abstract][Full Text] [Related]
28. Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.
Meerveld-Eggink A; Rozeman EA; Lalezari F; van Thienen JV; Haanen JBAG; Blank CU
Ann Oncol; 2017 Apr; 28(4):862-867. PubMed ID: 28158487
[TBL] [Abstract][Full Text] [Related]
29. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
Wang H; Ma H; Sové RJ; Emens LA; Popel AS
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
[TBL] [Abstract][Full Text] [Related]
30. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
[TBL] [Abstract][Full Text] [Related]
31. Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug.
Perlstein D; Shlagman O; Kogan Y; Halevi-Tobias K; Yakobson A; Lazarev I; Agur Z
PLoS One; 2019; 14(12):e0226869. PubMed ID: 31877168
[TBL] [Abstract][Full Text] [Related]
32. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
Jespersen H; Olofsson Bagge R; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
BMC Cancer; 2019 May; 19(1):415. PubMed ID: 31046743
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab plus ipilimumab in patients with metastatic melanoma.
Hodi FS; Lawrence D; Lezcano C; Wu X; Zhou J; Sasada T; Zeng W; Giobbie-Hurder A; Atkins MB; Ibrahim N; Friedlander P; Flaherty KT; Murphy GF; Rodig S; Velazquez EF; Mihm MC; Russell S; DiPiro PJ; Yap JT; Ramaiya N; Van den Abbeele AD; Gargano M; McDermott D
Cancer Immunol Res; 2014 Jul; 2(7):632-42. PubMed ID: 24838938
[TBL] [Abstract][Full Text] [Related]
34. Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma: Results of a Study of Academic and Community Cancer Research United (ACCRU) RU261206I.
Markovic SN; Suman VJ; Javed A; Reid JM; Wall DJ; Erickson LA; Ernstoff M; Anderson DM
Am J Clin Oncol; 2020 Feb; 43(2):115-121. PubMed ID: 31809326
[TBL] [Abstract][Full Text] [Related]
35. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma.
Spain L; Larkin J
Expert Opin Biol Ther; 2016; 16(3):389-96. PubMed ID: 26750801
[TBL] [Abstract][Full Text] [Related]
36. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
Kirchberger MC; Hauschild A; Schuler G; Heinzerling L
Eur J Cancer; 2016 Sep; 65():182-4. PubMed ID: 27501507
[TBL] [Abstract][Full Text] [Related]
37. A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade.
Milberg O; Gong C; Jafarnejad M; Bartelink IH; Wang B; Vicini P; Narwal R; Roskos L; Popel AS
Sci Rep; 2019 Aug; 9(1):11286. PubMed ID: 31375756
[TBL] [Abstract][Full Text] [Related]
38. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors.
Annovazzi A; Vari S; Giannarelli D; Pasqualoni R; Sciuto R; Carpano S; Cognetti F; Ferraresi V
Clin Nucl Med; 2020 Mar; 45(3):187-194. PubMed ID: 31977479
[TBL] [Abstract][Full Text] [Related]
39. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Krepler C; Ibrahim N; Marreaud S; van Akkooi A; Robert C; Suciu S
JAMA Oncol; 2020 Apr; 6(4):519-527. PubMed ID: 31895407
[TBL] [Abstract][Full Text] [Related]
40. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
